The DOI matches its Crossref record.
Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Open accessAbstract
Purpose: To identify druggable oncogenic fusions in invasive mucinous adenocarcinoma (IMA) of the lung, a malignant type of lung adenocarcinoma in which KRAS mutations frequently occur. Experimental Design: From an IMA cohort of 90 cases, consisting of 56 cases (62%) with KRAS mutations and 34 cases without (38%), we conducted whole-transcriptome sequencing of 32 IMAs, including 27 cases without KRAS mutations. We used the sequencing data to identify gene fusions, and then performed functional analyses of the fusion gene products. Results: We identified oncogenic fusions that occurred mutually exclusively with KRAS mutations: CD74-NRG1, SLC3A2-NRG1, EZR-ERBB4, TRIM24-BRAF, and KIAA1468-RET. NRG1 fusions were present in 17.6% (6/34) of KRAS-negative IMAs. The CD74-NRG1 fusion activated HER2:HER3 signaling, whereas the EZR-ERBB4 and TRIM24-BRAF fusions constitutively activated the ERBB4 and BRAF kinases, respectively. Signaling pathway activation and fusion-induced anchorage-independent growth/tumorigenicity of NIH3T3 cells expressing these fusions were suppressed by tyrosine kinase inhibitors approved for clinical use. Conclusions: Oncogenic fusions act as driver mutations in IMAs without KRAS mutations, and thus represent promising therapeutic targets for the treatment of such IMAs. Clin Cancer Res; 20(12); 3087–93. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
Inamura, K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00193 · Cited by 503
New and emerging targeted treatments in advanced non-small-cell lung cancer
Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 487
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 406
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 352
Metadata
- Authors
- Nakaoku, T., Tsuta, K., Ichikawa, H., Shiraishi, K., Sakamoto, H., Enari, M., Furuta, K., Shimada, Y., Ogiwara, H., Watanabe, S.-I., Nokihara, H., Yasuda, K., Hiramoto, M., Nammo, T., Ishigame, T., Schetter, A. J., Okayama, H., Harris, C. C., Kim, Y. H., Mishima, M., Yokota, J., Yoshida, T., & Kohno, T.
- Venue
- Clinical Cancer Research
- Published
- 2014-06-12
- Volume
- 20
- Issue
- 12
- Pages
- 3087-3093
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2155888371
- Cited by
- 206
- References
- 0
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0107
- The paper
- Nakaoku, T., Tsuta, K., Ichikawa, H., Shiraishi, K., Sakamoto, H., Enari, M., Furuta, K., Shimada, Y., Ogiwara, H., Watanabe, S.-I., Nokihara, H., Yasuda, K., Hiramoto, M., Nammo, T., Ishigame, T., Schetter, A. J., Okayama, H., Harris, C. C., Kim, Y. H., . . . Kohno, T. (2014). Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.